NLRP3 and Peritoneal Fibrosis: Treatment with ONO-AE3-208 significantly prevented peritoneal inflammation and peritoneal fibrosis by inhibiting activation of the NLRP3 inflammasome and reducing phosphorylation of NF-κB.